Marapharm Ventures Inc. Provides An Update Of Its Investment Strategy With Veritas Pharma Inc
KELOWNA, British Columbia, February 1, 2017 /PRNewswire/ --
Marapharm Ventures Inc. (OTCQB: MRPHF). Marapharm's focus is on corporate growth and excellence by acquisitions, operations and investments. Marapharm invested in Veritas Pharma Inc. "Veritas" (news releases January 9 and January 11, 2017, Marapharm purchased 15 million shares and rights to acquire shares) and to date, this investment has increased substantially in value. The synergy with Veritas and Marapharm and the development of both company's products enhances corporate and shareholder value overall. Medical research by Veritas scientists can help to monetize Marapharm's intellectual properties and products of subsidiaries currently under development. Marapharm, with the assistance of Veritas, intends to advance its cannabis strains. "With our unique vertical grow system, yields and quality will be maximized. We think Veritas is a great business model and investment in the cannabis space. Marapharm is the majority owner and largest shareholder of Veritas," Linda Sampson, Marapharm CEO.
Veritas and or its subsidiary Cannevert Therapeutics Ltd. "Veritas"" have designed and are implementing clinical trials of cannabis strains for pain. Health Canada has granted permission to conduct research. Chemical and animal studies by Veritas have identified suitable strains that warrant immediate human trials which are intended to be implemented this year. The management team consists of veteran academic pharmacologists, anaesthetists and chemists whose commercial mission is to patent its findings in order to sell or license to cancer clinics and pharmaceutical companies, thereby, targeting multi-billion dollar global markets.
ABOUT VERITAS PHARMA INC.
http://www.veritaspharmainc.com
Veritas trades in Canada, ticker symbol VRT on the CSE, in the United States, ticker symbol VRTHF on the OTC, in Europe, ticker symbol 2VP.F on the FSE.
Veritas is a discovery and development company, advancing the science behind medical marijuana. Veritas has brought together a highly accredited team of pharmacologists, anaesthetists and chemists with substantial success in both academia and industry, specifically in drug development. The Veritas laboratory is located within the University of British Columbia (UBC). Veritas applies a comprehensive scientific approach to medical marijuana claims. Veritas's mission has been to develop the most effective proprietary cannabis strains for specific disease conditions and to provide doctors and patients with conclusive science evidence to recommend and use medical marijuana with confidence. Veritas has an advanced application to Health Canada for a Medical Marijuana facility to be located in Sechelt, British Columbia and, the Canadian Government has said it will legalize marijuana for medical and recreational use. Veritas and its employee group consisting of several doctors work closely with Health Canada.
ABOUT MARAPHARM VENTURES INC.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for it's land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com ) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, 778-583-4476, email info@marapharm.com
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476, email info@marapharm.com
SOURCE Marapharm Ventures Inc.